



Fondazione
Epatocentro Ticino



Institute
for
Research
in
Biomedicine

Digital 3rd Swiss Autoimmune Liver Disease Meeting 2020

November 20th – 21st 2020

ONLINE

Course Organisers:

*Andreas Cerny, Switzerland,
Pietro Invernizzi, Italy
Giorgina Mieli-Vergani, UK
Benedetta Terziroli Beretta-Piccoli, Switzerland
Federica Sallusto, Switzerland
Diego Vergani, UK*

Contacts

Fondazione Epatocentro Ticino, Lugano

www.swissautoimmuneliver.ch

swissaidmeeting@epatocentro.ch

+41 91 960 8503

Credits

SSP Société Suisse de Pédiatrie : 11 credits

SGAIM: the meeting is allowed to be accredited for “formazione allargata SGAIM”

European CME credits (ECMEC®s): 10 credits, each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

SSAI Swiss Society for Allergology and Immunology: 11 credits

SGG SSG Schweizerische Gesellschaft für Gastroenterologie: 13 march: 6 credits; 14 march: 5 credits

SGPath SSPath Schweizerische Gesellschaft für Pathologie : 13 march: 6 credits; 14 march: 5 credit

ENDORSEMENTS



King's College Hospital NHS Foundation Trust



SSAI Société Suisse d'Allergologie et d'Immunologie
Schweizerische Gesellschaft für Allergologie und Immunologie
Swiss Society for Allergology and Immunology



Ente Ospedaliero Cantonale



SGPath SSPath
SOCIÉTÉ SUISSE DE PATHOLOGIE
SCHWEIZERISCHE GESELLSCHAFT FÜR PATHOLOGIE
SWISS SOCIETY OF PATHOLOGY





Fondazione
Epatocentro Ticino



Institute
for
Research
in
Biomedicine

SCIENTIFIC PROGRAMME

November 20th

- 11:00 – 11:10 Welcome and introduction
Andreas Cerny, Switzerland
Benedetta Terziroli Beretta-Piccoli, Switzerland
- 11:10 – 11:15 Welcome
Mario Bianchetti, founding Dean of the Master Medical School, Switzerland
- 11:15 – 11:20 Welcome
Richard Gelula, Chief of Operations, GLI Global Liver Institute

Basic science session 1

- Chairs:* *Andreas Cerny, Switzerland*
Federica Sallusto, Switzerland
- 11:20 – 11:40 Genetics in primary biliary cholangitis beyond GWAS
Pietro Invernizzi, Italy
- 11:40 – 11:50 Discussion
- 11:50 – 12:10 Preventing the progression of PBC
Eric Gershwin, USA
- 12:10 – 12:20 Discussion
- 12:20 – 12:40 Effector and regulatory T-cells in autoimmune diseases
Federica Sallusto, Switzerland
- 12:40 – 12:50 Discussion
- 12:50 – 14:00 Lunch & Poster viewing**

Basic science session 2

- Chairs:* *Michael Manns, Germany*
Pietro Majno-Hurst, Switzerland
- 14:00 – 14:20 The impact of gut microbiome on T-cell trafficking
Giandomenica Iezzi, Switzerland
- 14:20 – 14:30 Discussion
- 14:30 – 14:50 Novel approaches to autoantibody characterization
Antonio Lanzavecchia, Switzerland
- 14:50 – 15:00 Discussion
- 15:00 – 15:20 Immunometabolic drugs
Michael Trauner, Austria
- 15:20 – 15:30 Discussion



Fondazione
Epatocentro Ticino



Institute
for
Research
in
Biomedicine

15:30 – 15:50	Living in the Liver: overcoming constraints on T cells <i>Mala Maini, UK</i>
15:50 – 16:00	Discussion
16:00 – 16:20	Coffee break & Poster viewing
16:20 – 16:40	Anti-tumor autologous T-cell therapy for HBV-associated hepatocellular carcinoma <i>Antonio Bertoletti, Singapore</i>
16:40 – 16:50	Discussion
16:50 – 17:10	Animal model of autoimmune liver diseases <i>Urs Christen, Germany</i>
17:10 – 17:20	Discussion
17:20 – 17:40	Omics and personalized medicine for autoimmune liver diseases <i>Tom Hemming Karlsen, Norway</i>
17:40 – 17:50	Discussion
17:50 – 18:30	3 oral presentations selected among submitted abstract 1. Antibody-mediated clearance of serum HBsAg has minimal impact on CD8+ T cell responses in mouse models of HBV pathogenesis - <i>Dr. Valeria Fumagalli, Italy</i> 2. Cell specific transcriptomic analyses reveals a disassociation between treatment response and peripheral markers of immune activation in primary biliary cholangitis - <i>Dr. Evaggelia Liaskou, UK</i> 3. Preventing the Progression of PBC and other Autoimmune Live Diseases: Moving from the Conventional to the Plausible – <i>Prof. Eric Gershwin, USA</i>
18:30 – 18:40	What have we learned and what should we do next <i>Pietro Invernizzi, Italy</i>

November 21st

Clinical session 1

Chairs: *Andrea De Gottardi, Switzerland*
Maria Isabel Lucena, Switzerland

08:30 – 08:50	Bile duct lesions in autoimmune hepatitis and interface hepatitis in primary biliary cholangitis <i>Alberto Quaglia, UK</i>
08:50 – 09:00	Discussion
09:00 – 09:20	Autoimmune hepatitis type 2 <i>Giorgina Mieli-Vergani, UK</i>
09:20 – 09:30	Discussion



Fondazione
Epatocentro Ticino



Institute
for
Research
in
Biomedicine

09:30 – 09:50	Gut-liver axis <i>Antonio Moschetta, Italy</i>
09:50 – 10:00	Discussion
10:00 – 10:20	Coffee break & Poster viewing
10:20 – 10:40	There is more than one cause for primary sclerosing cholangitis <i>Richard Thompson, UK</i>
10:40 – 10:50	Discussion
10:50 – 11:10	Autoantibodies in autoimmune liver diseases: clinical aspects <i>Luigi Muratori, Italy</i>
11:10 – 11:20	Discussion
11:20 – 11:40	Beyond guidelines <i>Michael Manns, Germany</i>
11:40 – 11:50	Discussion
11:50 – 13:00	Lunch & Poster viewing
Clinical session 2	
<i>Chairs:</i>	
	<i>Eric Gershwin, USA</i> <i>Florian Bihl, Switzerland</i>
13:00 – 13:20	Drug-induced liver injury and autoimmunity <i>Raul Andrade, Spain</i>
13:20 – 13:30	Discussion
13:30 – 13:50	Post-transplant autoimmune liver diseases <i>Diego Vergani, UK</i>
13:50 – 14:00	Discussion
14:00 – 14:45	3 oral presentations selected among submitted abstract 1. Gamma-glutamyl transferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on the alkaline phosphatase – <i>Dr Alessio Gerussi, Italy</i> 2. Autoimmune Hepatitis in hospital practice in Cameroon: about 83 cases – <i>Dr. Canis Kuate Fossouo, Cameroon</i> 3. The PBC Foundation App: What Have We Learned and What Should We Do Next? – <i>Robert Mitchell-Thain, UK</i>
14:45 – 15:00	What have we learned and what should we do next <i>Eric Gershwin, USA</i>
15:00 – 15:10	Concluding remarks <i>Andreas Cerny, Benedetta Terzioli Beretta-Piccoli</i>